Genelux Corporation Common Stock (GNLX) Stock Price

GNLXStock

$2.72−28.04%52W

Market Cap$123.07M

P/E—

PEG Ratio—

Div yield—

Beta0.55

GNLX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-7.43%

Price vs S&P 500 (4W)-9.90%

VGM Score43.90

Book Value / Share (Quarterly)$0.52

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-91.03%

Cash Flow / Share (Quarterly)$-0.63

Price vs S&P 500 (YTD)-49.57%

Net Profit Margin (TTM)-115587.50%

EPS (TTM)$-0.85

10-Day Avg Trading Volume0.33M

EPS Excl Extra (TTM)$-0.85

EPS (Annual)$-0.86

ROI (Annual)-278.46%

Cash / Share (Quarterly)$0.59

ROA (Last FY)-168.94%

Revenue Growth TTM (YoY)0.00%

EBITD / Share (TTM)$-0.87

Operating Margin (TTM)-117650.00%

Cash Flow / Share (Annual)$-0.70

P/B Ratio5.15x

P/B Ratio (Quarterly)4.73x

Net Income / Employee (Annual)$-1,285,800

Net Interest Coverage (TTM)-6.59x

ROA (TTM)-123.65%

EPS Incl Extra (Annual)$-0.86

Current Ratio (Annual)2.43x

Quick Ratio (Quarterly)3.60x

3-Month Avg Trading Volume0.21M

52-Week Price Return-28.04%

Revenue / Employee (TTM)$300

Tangible BV / Share (Quarterly)$0.92

P/S Ratio (Annual)14741.29x

Asset Turnover (Annual)0.00x

52-Week High$8.54

EPS Excl Extra (Annual)$-0.86

CapEx CAGR (5Y)122.80%

26-Week Price Return3.82%

Quick Ratio (Annual)2.34x

13-Week Price Return-6.85%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.68x

Enterprise Value$108.66M

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$300

Pretax Margin (Annual)-401812.50%

Cash / Share (Annual)$0.39

3-Month Return Std Dev48.85%

Net Income / Employee (TTM)$-1,343,200

ROE (Last FY)-278.46%

Net Interest Coverage (Annual)-4.74x

EPS Basic Excl Extra (Annual)$-0.86

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.85

ROI (TTM)-174.55%

P/S Ratio (TTM)14741.29x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$-1.46

Price vs S&P 500 (52W)-46.35%

Year-to-Date Return-37.61%

5-Day Price Return4.62%

EPS Normalized (Annual)$-0.86

ROA (5Y Avg)-130.42%

Net Profit Margin (Annual)-401812.50%

Month-to-Date Return-7.48%

Cash Flow / Share (TTM)$-1.00

EBITD / Share (Annual)$-0.89

Operating Margin (Annual)-415175.00%

LT Debt / Equity (Annual)0.00x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.85

P/TBV (Quarterly)12.34x

P/B Ratio (Annual)14.37x

Pretax Margin (TTM)-115587.50%

Book Value / Share (Annual)$0.31

Price vs S&P 500 (13W)-9.64%

Beta0.55x

Revenue / Share (TTM)$0.00

ROE (TTM)-174.55%

52-Week Low$2.29

gGradeC

mGradeC

vgmGradeC

GNLX Earnings Surprise History

Q2 25-0.20est. -0.22

Q3 25-0.21est. -0.21

Q4 25-0.24est. -0.22

Q1 26-0.20est. -0.20

Q2 26-0.21est. -0.20

GNLX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.08

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
GNLXGenelux Corporation Common Stock	—	C	C	$2.72
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Genelux Corporation Common Stock

Genelux Corp is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for difficult-to-treat solid tumors. The company's lead candidate, olvimulogene nanivacirepvec (Olvi-Vec), is being evaluated for lung and pancreatic cancers. The approach leverages engineered viruses to activate the patient's immune system against cancer cells.